Last updated: July 23, 2026
What is the case caption, court, and parties in Apotex v. Alcon (1:16-cv-03145)?
Case: Apotex Inc. v. Alcon Research, Ltd.
Docket: 1:16-cv-03145
Parties:
- Plaintiff: Apotex Inc.
- Defendant: Alcon Research, Ltd.
What patent issues and claims were at stake in Apotex Inc. v. Alcon Research, Ltd. (1:16-cv-03145)?
No litigation-issues summary can be produced. The case docket and complaint-level details (asserted patents, claim construction, theories of infringement, invalidity grounds, product/drug identification, and final disposition) are required to produce a legally accurate litigation summary and business-useful analysis. Those records are not present in the provided input, and generating them without verification would not meet an analyst-grade standard.
What are the key procedural milestones in 1:16-cv-03145?
No verified milestone timeline can be produced. A factual chronology requires at minimum: complaint filing date, answer, amended pleadings, Markman order dates, summary judgment or motion-to-dismiss outcomes, trial dates, and any settlement or dismissal order. None of those dates or orders are included in the provided input.
How does the filing relate to Hatch-Waxman Paragraph IV and generic entry risk?
No verified Hatch-Waxman linkage can be produced. A Paragraph IV-driven litigation requires specific ties to an ANDA number and the Orange Book patents allegedly carved out, along with the asserted patent list and the statutory basis (35 U.S.C. § 271(e)(2)). Those identifiers are not included in the provided input.
What is the infringement and validity posture for the asserted patents?
No infringement/validity posture can be produced. A substantive analysis requires claim-by-claim mapping, asserted-claim numbers, legal standards used by the court (e.g., indefiniteness, anticipation, obviousness), and the court’s rulings. None are included in the provided input.
What does the outcome mean for exclusivity and launch timing?
No exclusivity/launch analysis can be produced. Launch timelines depend on: which patents were enjoined or survived, whether the court entered a judgment of non-infringement/invalidity, and whether any section viii settlement occurred. These are not present in the provided input.
What is the commercial and licensing impact for Apotex vs. Alcon?
No commercial impact can be quantified. Business impact analysis requires: the targeted branded product, market revenues, the generic’s intended dosage form and labeling, the patents-in-suit, and any licensing or settlement terms. None are provided.
Which other cases or later appeals affect 1:16-cv-03145?
No cross-case or appellate impact can be produced. An analyst-grade map needs: appeal docket numbers, related cases with the same patents, consolidated proceedings, and outcomes of any Federal Circuit review.
Key Takeaways
- Docket identified: 1:16-cv-03145 with Apotex Inc. as plaintiff and Alcon Research, Ltd. as defendant.
- Litigation substance (patents asserted, rulings, and outcome) is not provided, so a factual litigation summary and patent-strength analysis cannot be generated from the provided information.
FAQs
- What patents were asserted by Alcon Research in 1:16-cv-03145?
- Did Apotex’s filing involve an ANDA Paragraph IV certification, and which Orange Book patents were challenged?
- What dispositive rulings did the court issue (motion to dismiss, summary judgment, claim construction)?
- Was there a settlement or dismissal with a dated section viii agreement affecting generic entry?
- Are there related appeals in the Federal Circuit tied to 1:16-cv-03145?
References
- No cited sources were provided in the prompt.
